Bli medlem
Bli medlem

Du är här


Cantargia AB: Cantargia receives Notice of Allowance from USPTO on IL1RAP in acute lymphatic leukemia

The United States Patent and Trademark Office ("USPTO") has issued a
Notice of Allowance on Cantargia AB's ("Cantargia") patent
application regarding IL1RAP as a target molecule for antibody
therapy of acute lymphatic leukemia (ALL).

The patent application with application number 13/390,459 which has
now obtained Notice of Allowance by the USPTO concerns the company's
method to use IL1RAP as a target molecule for the treatment of
hematological cancers. As a first step the USPTO plans to issue a
patent on IL1RAP as a target molecule for antibody based therapy of
ALL. As a subsequent step Cantargia is preparing a divisional
application to obtain granted claims on areas outside ALL. This means
that the examination will continue around the other parts of the
original application, ie other hematological forms of cancer.

The issuance of a Notice of Allowance indicates that the USPTO intends
to approve the company's patent application. Certain administrative
steps remain before the patent is formally granted.

"Our patent portfolio is progressing and the information from USPTO
gives further validation of IL1RAP as a unique target molecule" says
Göran Forsberg, CEO of Cantargia AB. "It is a welcome notice, as USA
is the biggest market for cancer therapies."

For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46 275 62 60


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.